AGR Summary
Anadys Pharmaceuticals, Inc.
(NASD:ANDS)
Average
(72)
| Industry: | Biotechnology | Period End: | Mar 31, 2010 (Fiscal 2010 Q-1) | Statement Filing: | Apr 28, 2010 (10-Q) |
|---|---|---|---|---|---|
| Market Cap: | USD 78.2mm (Micro Cap) | Last Audit: | Ernst & Young LLP | Rating Published: | Jun 18, 2010 |
OVERVIEW
Anadys Pharmaceuticals, Inc.
is currently rated as having
Average Accounting & Governance Risk (AGR).
This places them in the 72nd
percentile among all companies, indicating higher accounting and governance risk than
28% of companies.
RISK SUMMARY
The forensic risk summary highlights material risks, if any, and lists the most material red flagged metric for each risk. AGR Impact shows the relative weight of the various red flagged metrics by risk type.
| Risk | AGR Impact | Top Flagged Metric |
|---|---|---|
| Corporate Governance Events | 0.0% | |
| High Risk Events | 27.0% | Restructuring |
| Revenue Recognition | 0.0% | |
| Expense Recognition | 43.5% | Prepaid Expenses/Operating Expense |
| Asset-Liability Valuation | 29.5% | Liquidity: Cash Ratio |